DMAA
Drugs Made In America Acquisition Corp. Ordinary SharesNASDAQFinancial Services$10.51+0.10%ClosedMarket Cap: $352.3M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
61.51
PEG
—
P/B
1.05
P/S
0.00
EV/EBITDA
-484.85
DCF Value
—
FCF Yield
-0.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
3.4%
ROA
2.4%
ROIC
-0.3%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $0.00 | $2.2M | $0.07 |
| Q2 2025 | $0.00 | $2.3M | $0.07 |
| Q1 2025 | $0.00 | $1.3M | $49.18 |
| Q4 2024 | $0.00 | $-279.00 | $-0.03 |
Trading Activity
Insider Trades
View AllDrugs Made In America Acquisition LLC10 percent owner
BuyTue Feb 18
Stockwell Lynndirector, 10 percent owner, officer: CEO and Exe. Chair of Board
BuyTue Feb 18
Drugs Made In America Acquisition LLC10 percent owner
BuyTue Feb 04
Drugs Made In America Acquisition LLC10 percent owner
SellTue Feb 04
Drugs Made In America Acquisition LLC10 percent owner
SellTue Feb 04
Company Info
Sector
Financial Services
Industry
—
Country
US
Exchange
NASDAQ
Beta
-0.00
Drugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.